279 related articles for article (PubMed ID: 33933172)
21. Oocyte vitrification for elective fertility preservation: a SWOT analysis.
Gil-Arribas E; Blockeel C; Pennings G; Nekkebroeck J; Velasco JAG; Serna J; De Vos M
Reprod Biomed Online; 2022 Jun; 44(6):1005-1014. PubMed ID: 35304091
[TBL] [Abstract][Full Text] [Related]
22. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
23. Five years' experience using oocyte vitrification to preserve fertility for medical and nonmedical indications.
Garcia-Velasco JA; Domingo J; Cobo A; Martínez M; Carmona L; Pellicer A
Fertil Steril; 2013 Jun; 99(7):1994-9. PubMed ID: 23465707
[TBL] [Abstract][Full Text] [Related]
24. Cryopreservation of human embryos and oocytes for fertility preservation in cancer and non cancer patients: a mini review.
Sciorio R
Gynecol Endocrinol; 2020 May; 36(5):381-388. PubMed ID: 32003268
[TBL] [Abstract][Full Text] [Related]
25. Live birth using vitrified--warmed oocytes in invasive ovarian cancer: case report and literature review.
Alvarez M; Solé M; Devesa M; Fábregas R; Boada M; Tur R; Coroleu B; Veiga A; Barri PN
Reprod Biomed Online; 2014 Jun; 28(6):663-8. PubMed ID: 24745835
[TBL] [Abstract][Full Text] [Related]
26. Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue.
Yin H; Jiang H; Kristensen SG; Andersen CY
J Assist Reprod Genet; 2016 Jun; 33(6):741-6. PubMed ID: 26984232
[TBL] [Abstract][Full Text] [Related]
27. Modeling of live-birth rates and cost-effectiveness of oocyte cryopreservation for cancer patients prior to high- and low-risk gonadotoxic chemotherapy.
Lyttle Schumacher B; Grover N; Mesen T; Steiner A; Mersereau J
Hum Reprod; 2017 Oct; 32(10):2049-2055. PubMed ID: 28938728
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in fertility preservation.
Dolmans MM; Manavella DD
J Obstet Gynaecol Res; 2019 Feb; 45(2):266-279. PubMed ID: 30246274
[TBL] [Abstract][Full Text] [Related]
29. Oocyte vitrification offers more space for a tailored surgical management of endometriosis.
Pluchino N; Roman H
Reprod Biomed Online; 2020 Nov; 41(5):753-755. PubMed ID: 32819840
[TBL] [Abstract][Full Text] [Related]
30. Fertility preservation after fertility-sparing surgery in women with borderline ovarian tumours.
Khiat S; Provansal M; Bottin P; Saias-Magnan J; Metzler-Guillemain C; Courbiere B
Eur J Obstet Gynecol Reprod Biol; 2020 Oct; 253():65-70. PubMed ID: 32784054
[TBL] [Abstract][Full Text] [Related]
31. Why all women should freeze their eggs.
Cobo A; García-Velasco JA
Curr Opin Obstet Gynecol; 2016 Jun; 28(3):206-10. PubMed ID: 27031375
[TBL] [Abstract][Full Text] [Related]
32. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
33. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients?
Cobo A; Garcia-Velasco JA; Domingo J; Remohí J; Pellicer A
Fertil Steril; 2013 May; 99(6):1485-95. PubMed ID: 23541405
[TBL] [Abstract][Full Text] [Related]
34. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response.
Alvarez RM; Ramanathan P
Hum Reprod; 2018 Nov; 33(11):2051-2059. PubMed ID: 27370358
[TBL] [Abstract][Full Text] [Related]
35. Preservation of female fertility: The current therapeutic strategy.
Henry L; Labied S; Jouan C; Nisolle M
Int J Gynaecol Obstet; 2022 Jan; 156(1):3-9. PubMed ID: 33829509
[TBL] [Abstract][Full Text] [Related]
36. Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM.
Sellami I; Mayeur A; Benoit A; Zeghari F; Peigné M; Roufael J; Grynberg M; Sonigo C
J Assist Reprod Genet; 2023 Mar; 40(3):473-480. PubMed ID: 36752941
[TBL] [Abstract][Full Text] [Related]
37. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation.
Sermondade N; Sonigo C; Sifer C; Valtat S; Ziol M; Eustache F; Grynberg M
Fertil Steril; 2019 Feb; 111(2):357-362. PubMed ID: 30527837
[TBL] [Abstract][Full Text] [Related]
38. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
[TBL] [Abstract][Full Text] [Related]
39. Elective oocyte freezing for nonmedical reasons: a 6-year report on utilization and in vitro fertilization results from a Swedish center.
Wennberg AL; Schildauer K; Brännström M
Acta Obstet Gynecol Scand; 2019 Nov; 98(11):1429-1434. PubMed ID: 31173348
[TBL] [Abstract][Full Text] [Related]
40. Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible.
Sermondade N; Grynberg M; Comtet M; Valdelievre C; Sifer C; Sonigo C
Sci Rep; 2020 Oct; 10(1):18555. PubMed ID: 33122722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
